{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:29:52Z","timestamp":1794274192251,"version":"4.9.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Beyond cure, major goals in patients with Hodgkin lymphoma (HL) are tailoring treatment to a patient\u2019s individual risk for relapse to reduce acute and late toxicities, identifying candidates for early incorporation of novel agents, and making treatment affordable on a global level. Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) sequencing emerged as a promising strategy to achieve these goals; however, previous studies differed in sampling time points, assay validation, and definitions for MRD negativity. Here, we applied LymphoVista, a validated ctDNA sequencing assay for genotyping and MRD monitoring in lymphoma, to samples obtained from the German Hodgkin Study Group (GHSG) HD21 trial after 2 cycles of treatment (MRD-2) using a case-cohort design. Patients with positive MRD-2 result were at higher risk for relapse, progression, or death compared with MRD-2\u2013negative patients (4-year progression-free survival [PFS], 36.7% vs 82.2%; hazard ratio, 5.3; 95% confidence interval, 2.0-13.8; P = .0008). After inverse probability weighting accounting for the number of events in the full reference set, patients with positive and negative MRD-2 results had 4-year PFS rates of 72.2% vs 95.3%. Combining MRD-2 with positron emission tomography after 2 cycles of BrECADD\/eBEACOPP (PET-2) can identify patients at very low and patients at very high risk of relapse, progression, or death. In summary, these results suggest that MRD-2 assessment by LymphoVista allows for early outcome prognostication in patients with HL and could be used as a tool to improve treatment guidance on its own or in conjunction with PET-2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031089","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:11:36Z","timestamp":1770671496000},"page":"2194-2202","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-8504","authenticated-orcid":false,"given":"Jan-Michel","family":"Heger","sequence":"first","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"4Mildred Scheel School of Oncology Aachen Bonn Cologne D\u00fcsseldorf and Faculty of Medicine and University Hospital Cologne, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-0351","authenticated-orcid":false,"given":"Julia","family":"Mattlener","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kaul","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-7997","authenticated-orcid":false,"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-819X","authenticated-orcid":false,"given":"Jessica","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Schleifenbaum","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundolf","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdete","family":"Schaub","sequence":"additional","affiliation":[{"name":"6Department II of Internal Medicine, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-3037","authenticated-orcid":false,"given":"Johannes C.","family":"Hellmuth","sequence":"additional","affiliation":[{"name":"8Department of Medicine III, Ludwig Maximilian University Hospital Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Dierlamm","sequence":"additional","affiliation":[{"name":"9University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Martin","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mathas","sequence":"additional","affiliation":[{"name":"11Hematology, Oncology, and Cancer Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Berlin, Germany"},{"name":"12Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association, Biology of Malignant Lymphomas, Berlin, Germany"},{"name":"13Experimental and Clinical Research Center, a joint cooperation between Charit\u00e9 and Max Delbr\u00fcck Center, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[{"name":"14Hematology, Oncology and Rheumatology, Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Michiel","family":"Pegtel","sequence":"additional","affiliation":[{"name":"15Cancer Center Amsterdam, Imaging and Biomarkers and Department of Pathology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-5922","authenticated-orcid":false,"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam and HOVON Imaging Working Group, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ossowski","sequence":"additional","affiliation":[{"name":"17West German Genome Center and Cologne Center for Genomics, Medical Faculty, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7897-7181","authenticated-orcid":false,"given":"Kerstin","family":"Becker","sequence":"additional","affiliation":[{"name":"17West German Genome Center and Cologne Center for Genomics, Medical Faculty, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-4455","authenticated-orcid":false,"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"5German Hodgkin Study Group, Cologne, Germany"},{"name":"18Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, German Cancer Consortium (Partner Site Essen), Essen, Germany"},{"name":"19Cancer Center Cologne Essen-Partner Site Essen, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen\u2013Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"5German Hodgkin Study Group, Cologne, Germany"},{"name":"20Liqomics GmbH, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2026050711215553900_bib1","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026050711215553900_bib2","author":"Engert","year":"2020","edition":"3rd ed"},{"issue":"18","key":"2026050711215553900_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050711215553900_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10450","key":"2026050711215553900_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2026050711215553900_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2026050711215553900_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"2026050711215553900_bib8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(16)30093-6","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin\u2019s lymphoma: a longitudinal study of the German Hodgkin Study Group","volume":"17","author":"Kreissl","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026050711215553900_bib9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026050711215553900_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050711215553900_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41375-018-0240-8","article-title":"Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)","volume":"33","author":"Borchmann","year":"2019","journal-title":"Leukemia"},{"issue":"26","key":"2026050711215553900_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Michael","year":"2015","journal-title":"N Engl J Med"},{"issue":"10114","key":"2026050711215553900_bib13","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"The Lancet"},{"issue":"6","key":"2026050711215553900_bib14","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026050711215553900_bib15","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7996","key":"2026050711215553900_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"22","key":"2026050711215553900_bib17","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"35","key":"2026050711215553900_bib18","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026050711215553900_bib19","doi-asserted-by":"crossref","first-page":"1171.e11-1193.e11","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"suppl 1","key":"2026050711215553900_bib20","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2024-205034","article-title":"Lymphovista HL - a validated assay for genotyping and MRD assessment in Hodgkin lymphoma [abstract]","volume":"144","author":"Mattlener","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026050711215553900_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/EDE.0000000000001469","article-title":"The case for case\u2013cohort: an applied epidemiologist\u2019s guide to re-framing case-cohort studies to improve usability and flexibility","volume":"33","author":"O\u2019Brien","year":"2022","journal-title":"Epidemiology"},{"issue":"6","key":"2026050711215553900_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026050711215553900_bib23","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"key":"2026050711215553900_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/CLEP.S357494","article-title":"Inverse probability weighting enhances absolute risk estimation in three common study designs of nosocomial infections","volume":"14","author":"Staus","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2026050711215553900_bib25","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.14.25325806","article-title":"The DIRECT study: a roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in diffuse large B cell lymphoma","author":"Krupka","year":"19  2025","journal-title":"medRxiv"},{"issue":"9","key":"2026050711215553900_bib26","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s00259-021-05403-2","article-title":"Moving the goalposts while scoring\u2014the dilemma posed by new PET technologies","volume":"48","author":"Rogasch","year":"2021","journal-title":"Eur J Nucl Med Mol"},{"issue":"28","key":"2026050711215553900_bib27","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026050711215553900_bib28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"S3","key":"2026050711215553900_bib29","doi-asserted-by":"crossref","first-page":"e21_70093","DOI":"10.1002\/hon.70093_21","article-title":"Prognostic value of circulating tumor DNA in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 [abstract]","volume":"43","author":"Paczkowska","year":"2025","journal-title":"Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2194\/2517442\/blood_bld-2025-031089-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2194\/2517442\/blood_bld-2025-031089-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:22:04Z","timestamp":1778167324000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/19\/2194\/566484\/MRD-2-in-the-GHSG-HD21-trial-assessed-by-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":29,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031089","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,7]]},"published":{"date-parts":[[2026,5,7]]}}}